News | Contrast Media | March 13, 2017

European Committee Releases New Recommendations on Gadolinium-based Contrast Agents

Committee recommends suspension of marketing authorization for four linear gadolinium contrast agents that are more likely to leave deposits in the brain following MRI exams

PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI

March 13, 2017 — The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new recommendations on procedures employing gadolinium-based contrast agents, in which the committee recommended suspension of marketing authorization for four agents.

The EMA initiated a review last March of the risk of gadolinium deposition in brain tissue following the repeated use of gadolinium contrast agents in patients undergoing magnetic resonance imaging (MRI) scans.1 After carrying out an almost year-long, in-depth review of the risk of brain deposits and of the overall safety of these products, the PRAC recommendations2 are as follows:

“EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorizations for four linear gadolinium contrast agents because of evidence that small amounts of the gadolinium they contain are deposited in the brain.

The agents concerned are intravenous injections of gadobenic acid, gadodiamide, gadopentetic acid and gadoversetamide, which are given to patients to enhance images from magnetic resonance imaging (MRI) body scans. (...)

The four agents recommended for suspension are referred to as linear agents. Linear agents have a structure more likely to release gadolinium, which can build up in body tissues.

Other agents, known as macrocyclic agents, are more stable and have a much lower propensity to release gadolinium. The PRAC recommends that macrocyclic agents3 be used at the lowest dose that enhances images sufficiently to make diagnoses and only when unenhanced body scans are not suitable.

Some linear agents will remain available: gadoxetic acid, a linear agent used at a low dose for liver scans, can remain on the market as it meets an important diagnostic need in patients with few alternatives. In addition, a formulation of gadopentetic acid injected directly into joints is to remain available because its gadolinium concentration is very low – around 200 times lower than those of intravenous products. Both agents should be used at the lowest dose that enhances images sufficiently to make diagnoses and only if unenhanced scans are not suitable. (...)”

The recommendations also note that “the companies concerned by this review have the right to request the PRAC to re- examine its recommendations.

The PRAC’s final recommendations will be sent to the Committee for Medicinal Products for Human Use (CHMP) for its opinion. Further details will be published at the time of the CHMP opinion.”

Guerbet, which markets the macrocyclic gadolinium-based contrast agents Dotarem and Artirem, as well as Optimark, a product belonging to the class of linear gadolinium-based contrast agents, voiced its agreement with the PRAC recommendations and said it does not intend to request a re-examination. The company said it is strongly committed to providing healthcare professionals with a comprehensive range of effective and safe contrast media in order to improve diagnosis, prognosis and quality of life for patients.

Watch the ITNtv video “MRI Gadolinium Contrast Retention in the Brain.”

Read the ITN feature story “Gadolinium May Remain in Brain After Contrast MRI.”

For more information: www.ema.europa.eu

References

1. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium- containing_contrast_agents/human_referral_prac_000056.jsp&mid=WC0b01ac05805c516f
2. Gadolinium Article-31 referral - PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations. 10/03/2017

Related Content

The study finds it's possible to use commercial facial recognition software to identify people from brain MRI that includes imagery of the face
News | Magnetic Resonance Imaging (MRI) | November 15, 2019
November 15, 2019 — Though identifying data typically are removed from medical image files before they are shared for

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...
An image on Brigham and Women's Hospital's 7T MRI system

An image on Brigham and Women's Hospital's 7T MRI system. Image courtesy of Brigham and Women's Hospital

News | Magnetic Resonance Imaging (MRI) | November 13, 2019
November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may b
Radiographer Apollo Exconde with his Lego concept open MRI for patient education.

Radiographer Apollo Exconde with his Lego concept open MRI for patient education.

News | Patient Engagement | November 11, 2019
November 11, 2019 — Radiographer Apollo Exconde...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
The introduction of liquid helium free, high-end MRI systems by MR Solutions substantially reduces the environmental impact
News | Magnetic Resonance Imaging (MRI) | November 05, 2019
November 5, 2019 — Environmental impact is becoming a significant factor in the selection of suppliers even in precli
MRI control room at Centra DuPage Hospital
News | Magnetic Resonance Imaging (MRI) | November 04, 2019
November 4, 2019 — Traditional image-guided procedures remained restricted to the limitation of physicians referring
Windsong Radiology Group

Windsong Radiology Group

Sponsored Content | Case Study | Contrast Media Injectors | October 30, 2019
Windsong Radiology Group is a New York-based radiolo
The Neuroreader software program quantifies brain volume in study participants with TBI

The Neuroreader software program quantifies brain volume in study participants with TBI. Image courtesy of UCLA Health.

News | Clinical Trials | October 29, 2019
October 29, 2019 — A UCLA-led...